Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and Empagliflozin in T1D with AID (SEMPA)
NCT06894784Phase 3Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide, empagliflozin in type 1 diabetes mellitus (T1D), sponsored by McGill University Health Centre. Started Apr 2025; status: recruiting.
02
Drugs
semaglutideempagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06894784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06894784.